-
Posted by
Two Blokes Jul 22 -
Filed in
Stock
-
6 views
Novo Nordisk holds 72% international and 50%+ U.S. market share in GLP-1 treatments, serving 46 million patients globally. Obesity drug sales surged 65% YoY in Q1-FY25, driving total revenue growth of 18% and free cash flow of $1.38 billion. The company projects FY25 free cash flow between $8.14–$9.59 billion, supported by 48.43% EBIT margins and expanding manufacturing capacity.
